Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The bioAffinity Technologies, Inc. (BIAF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer, bioAffinity Technologies files current reports, proxy statements, registration statements and financial reports that describe its biotechnology business focused on noninvasive diagnostics and early detection of lung cancer and other lung diseases.
Through its filings, investors can review Form 8-K current reports detailing material events such as College of American Pathologists (CAP) accreditation for its subsidiary Precision Pathology Laboratory Services, notifications of allowance for U.S. and international patents protecting the CyPath® Lung platform, presentations at major medical conferences and capital-raising transactions, including registered direct offerings under an effective Form S-3 shelf registration statement. These 8-Ks also summarize developments related to Nasdaq listing compliance and monitoring.
Definitive proxy statements filed on Schedule 14A outline governance and capital structure proposals, such as warrant exercise and anti-dilution provisions, preferred stock terms, amendments to equity incentive plans and potential non-public offerings under Nasdaq rules. Together with periodic reports, these documents help explain how bioAffinity Technologies manages its equity, financing options and incentive programs while advancing CyPath® Lung and its diagnostic platform.
On Stock Titan, AI-powered tools can assist in reviewing lengthy filings by highlighting key sections related to revenue sources, laboratory operations, patent portfolio, Nasdaq compliance and financing terms. Users can quickly locate disclosures about the marketing of CyPath® Lung as a Laboratory Developed Test through Precision Pathology Laboratory Services, CAP and CLIA credentials, and the scope of the company’s global patent estate. Real-time EDGAR updates ensure that new BIAF filings, including future 10-K annual reports, 10-Q quarterly reports, 8-K current reports and proxy materials, are surfaced promptly, while AI summaries help interpret complex legal and financial language.
bioAffinity Technologies, Inc. filed a prospectus supplement describing a common stock offering at an offering price of
bioAffinity Technologies, Inc. (BIAF) prospectus excerpts show a public offering priced at $2.50 per share with placement agent fees of $0.20 per share, producing proceeds before expenses of $2.30 per share and aggregate proceeds of $4,414,421.31. Historical net tangible book value per share was $0.20; the pro forma increase attributable to the offering is $0.99, producing a pro forma as-adjusted net tangible book value per share of $1.19. The filing notes Total capitalization of $(2,136,108) and references shares issuable upon conversion of 715.5 Series B Convertible Preferred shares at an initial conversion price of $6.90 per share.
Roberto Rios, a director of bioAffinity Technologies, Inc. (BIAF), filed an initial Form 3 disclosing beneficial ownership of 833 shares of the company's common stock. The event requiring the statement occurred on 08/12/2025 and the Form 3 bears a signature date of 09/25/2025. The filing indicates direct ownership and does not disclose any derivative securities or indirect holdings.
bioAffinity Technologies (BIAF) Form 3 — initial ownership disclosure. John J. Oppenheimer, listed as a Director, filed an initial Form 3 reporting that no securities are beneficially owned by him as of the event date 08/12/2025. The form shows the reporting relationship, the issuer symbol BIAF, and a signature dated 09/25/2025.
bioAffinity Technologies, Inc. filed an S-1 registration disclosing an assumed public offering price of $5.48 per share and pro forma capital impacts tied to that offering. The company reported a historical net tangible book value per share of $(1.30) as of June 30, 2025. Pro forma adjustments related to the offering increase net tangible book value by $2.06 to a pro forma as adjusted net tangible book value per share of $0.76. The filing shows a reported dilution to new investors of $4.72 per share. Additional disclosed items include conversion mechanics for Series B Convertible Preferred Stock (conversion price noted as $6.90 per share) and line items for additional paid-in capital and total capitalization figures included in the filing tables.
bioAffinity Technologies, Inc. filed a Current Report on Form 8-K disclosing a corporate action: the company announced a Reverse Stock Split and furnished a related press release dated September 17, 2025. The filing also includes a Certificate of Amendment to the Certificate of Incorporation as Exhibit 3.1, and the press release is furnished as Exhibit 99.1. The 8-K indicates these documents are part of the company's report of a material event but does not provide the split ratio or detail any effects on shares outstanding, shareholder approvals, or listing status within the disclosed text.
FAQ
What is the current stock price of bioAffinity Tech (BIAF)?
What is the market cap of bioAffinity Tech (BIAF)?
